anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a single domain antibody specifically binding to CLL1 protein and application thereof. Specifically disclosed is a single domain antibody having the amino acid sequence of SEQ ID No. 1. The single-domain antibody has high affinity, can well specifically target CLL1 positive cells, can effectively promote NK cells to secrete IFNgamma, activate the effector function of the NK cells, can obviously induce the cytotoxicity of the NK cells, and has stronger capability of specifically killing the CLL1 positive cells. The single domain antibody of the invention can be prepared into medicines for clinically preventing or treating CLL1 target related diseases, and can also be used for preparing CAR cells targeting CLL1 or detection kits of CLL1 proteins. The single domain antibody has stable medicine structure, small molecule, easy recombination expression and low production cost, can be used alone or used as a medicine carrying system to carry related medicines, and has very broad prospect and important significance in the fields of medicine application, clinical diagnosis and the like.
Preoperative treatment: three cycles of SOX. Radical gastrectomy and lymphadenectomy (D2). Postoperative treatment: five cycles of SOX.
<P>PROBLEM TO BE SOLVED: To obtain a therapeutic agent for hemorrhoid capable of improving symptoms of hemorrhoid excluding anal fistula and having high safety and effectiveness.  <P>SOLUTION: This therapeutic agent for hemorrhoid comprises one or more kinds of a mixture selected from the group consisting of tranexamic acid, tranexamic acid derivatives and salts thereof and a pharmaceutically acceptable hydrophobic base. According to the present invention, symptoms such as swelling and bleeding of an affected area and the circumference of the affected area can be salved without causing vasoconstriction, and symptoms of hemorrhoid excluding anal fistula can be ameliorated. The therapeutic agent is excellent in topically retaining properties of tranexamic acid compounds which are active ingredients and has long release time of these acid compounds. As a result, the therapeutic agent has higher safety and effectiveness, compared with conventional therapeutic agents for hemorrhoid.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
There has been mounting evidence of respiratory problems related to military service in the Middle East especially in the past two decades. An overview by Flavo et al. summarizes studies not only of soldiers but evaluation of particulates from the Middle East in a number of animal models. While there have been some 'prospective' studies based on use of a standard evaluation protocol post deployment, the primary imaging modalities have been chest radiograph (most read as normal) and chest high resolution computed tomography (HRCT), neither of which have significant functional information. Standard pulmonary function testing (e.g. spirometry, lung volumes, diffusing capacity, bronchoalveolar lavage, as well as oscillatory resistance) were used in the STAMPEDE study, but only provide global functional information. The case study by King et al. included lung biopsy in a sub-cohort (n = 49) of soldiers with varying degrees of inhalation exposure during deployment. All biopsy samples were abnormal and some were consistent with constrictive bronchiolitis. Constrictive bronchiolitis is a non-reversible bronchiolar airway disease that is characterized by fibrosis of the bronchioles and can be challenging to diagnose without biopsy (it is also known by the term 'bronchiolitis obliterans'). The chest radiographs were normal in these subjects although about 25% of chest CT showed 'air trapping' or 'centrilobular nodules'. Pulmonary function testing in 39 soldiers with HRCT showed normal to near normal results in 32 of the subjects, with seven showing low diffusion capacity, obstruction and/or restriction. Clearly, neither global measures of lung function nor high resolution anatomic imaging are sensitive enough to avoid a biopsy to confirm diagnosis of constrictive bronchiolitis. We hypothesize that measures of regional lung function should provide additional information to aid in the diagnosis of WLI and may assist in the management of more difficult or advanced cases of WLI.

This is an open label study in up to 10 subjects being evaluated for post war lung injury. Each subject will receive up to 25 liters of inert perfluoropropane/oxygen gas mixtures as a contrast agent to visualize the airway and alveolar spaces in their lungs using 19F magnetic resonance imaging of inert gas/oxygen mixtures.
FIELD: veterinary medicine. SUBSTANCE: method involves using vegetative culture of vaccinial capsules anthrax strain STI-1 as antigen for hyperimmunizing producer horses. Hyperimmunization is carried out in two stages. First, five injections of the antigen are subcutaneously administered concurrently at increasing doses from 0.4-0.6 to 4.0-6.0 milliards of microbial cells and intracutaneously administered at constant doses from 8.0-12.0 to 78.0-126.0 milliards of cells. The second stage involves subcutaneously administering eight injections of the antigen at increasing doses from 8.0-12.0 to 78.0-126.0 milliards of cells. Pause between the injections is 3-4 days long. Blood is taken from each serum producer 7-9 days later, after the hyperimmunization is over. The serum is used for treating and preventing anthrax. The preparation is administered subcutaneously or intra muscularly. EFFECT: high therapeutic and protective activity; wider range of applications. 3 tbl
Foods such as butter, margarine, cheese, bread, meat and sausages in skins and pharmaceutical, cosmetic &c. preparations are protected against atmospheric &c. deterioration by coating them with a film of an aqueous emulsion comprising a synthetic resin, a plasticizer and illupi oil, and drying the film.  The film may be gas-permeable or impermeable or alternatively the foods &c, particularly cheese, may be coated with a gas-permeable and then with a gas-impermeable protective film.  An emulsion providing a gas-permeable film may contain polyvinyl acetate, carboxymethyl cellulose, starch, citrus pectin, glycerol triacetate and glycerol.  An emulsion providing a gas-impermeable film may contain polyvinyl pyrrolidone and polyvinyl chloride, e.g. mixed with polyvinyl acetate or polyvinylidene chloride or polymethyl methacrylate, and a fungicide such as the sodium salt of methyl p-hydroxybenzoic, sorbic or methyl o-salicylic acid. Cadmium sulphate may be added to the emulsion as a protection against radioactive emanations and silicone oil may be added to prevent foaming.  It is stated that the illupi oil renders the coating film frost-resistant when the foods &c. are in deep-freeze storage.  Specification 761,856 is referred to.
The present invention discloses a medicament which has the functions of relieving inflammation, alleviating pain, reducing edema, dispelling stasis, dredging channels and removing stagnation, and is mainly prepared from medicaments having the functions of dispelling wind and eliminating dampness in group A and medicaments having the function of dispelling stasis in group B according to the proportion of 10: 3 to 4. The medicament not only can dispel wind, phlegm and damp stasis, but also has very good efficiency of dredging channels, dredging collaterals, softening and resolving hard mass, expelling blood stasis and removing stagnation. The two functions complement each other, and therefore, strong functions of dredging channels, activating collaterals, expelling blood stasis and removing stagnation are generated. The stagnant blockade of the channels and the collaterals of human tissues and organs can be rapidly dredged, and the goal that the channels and the collaterals are dredged, pains disappear, and diseases do not appear is achieved. Therefore, the medicament cures various kinds of inflammation, pain, sore furuncle apostasis, ulcers, comedo, acne, hemorrhoids, external injuries caused by knocks and falls, indigestion in the stomach and intestine, dyspepsia and various kinds of qi stasis blocking, blood stasis blocking, phlegm stasis blocking and damp stasis blocking. The medicament is a pure traditional Chinese medicine preparation with a stronger wide popularization characteristic.
BACKGROUND: In the U.S., uptake of the HPV vaccine remains below coverage goals. There is concern that negative reactions to emergency initiatives during the COVID-19 pandemic, including vaccination, may have increased some parents' hesitancy towards all vaccines, including HPV. Understanding how different parent populations view routine vaccination post-pandemic is key to strategic efforts to maintaining and increasing uptake of HPV vaccine.
METHODS: In early 2022, we recruited an online panel of English-speaking U.S. parents and caregivers, who used the social media platform Twitter and had HPV vaccine-eligible but unvaccinated children age 9-14 years. Respondents completed a 20-minute survey measuring knowledge, attitudes and intentions regarding HPV vaccination for their child, as well as background socio-demographics and health information-seeking practices. Questions regarding experiences during the COVID-19 pandemic included changes in access to preventive care, and perceptions of whether pandemic experiences had positively or negatively affected their attitudes about routine vaccination, with open text capturing reasons for this change.
RESULTS: Among 557 respondents, 81 % were definitely or likely to vaccinate their child against HPV, with 12 % being uncertain, and 7 % unlikely to vaccinate. Regarding routine vaccination, most (70 %) felt their attitudes had not changed, while 26 % felt more positively, and only 4 % felt more negatively. Reasons for positive attitude change included increased appreciation for vaccines overall, and motivation to proactively seek preventive care for their child. Negative attitude changes stemmed from distrust of COVID-19 public health efforts including vaccine development, and disillusionment with vaccines' ability to prevent disease. In multivariable models, intention to vaccinate was greater among parents reporting greater education, Democratic affiliation, greater religiosity, and urban residence. Negative attitude change due to the pandemic independently predicted reduced HPV vaccination intention, while positive attitude change predicted positive intention.
CONCLUSIONS: Post-pandemic, most U.S. parents remain committed to vaccinating their children against HPV. However, addressing residual COVID-19 concerns could improve uptake among vaccine-hesitant parents.
The present invention is directed to electrostatic chucks, methods for their use, the electrostatic deposition of objects, such as particles in a dry powder, onto recipient substrates, and the recipient substrates themselves that have been subjected to electrostatic deposition. In one aspect, the present invention provides an electrostatic chuck for electrostatically attracting an object or objects wherein the object is used in chemical or pharmaceutical assaying or manufacturing. The objects can be pharmaceutical substrates, for example, such as a pharmaceutical tablet. Additional embodiments of the invention provide chucks and their use to electrostatically attract particles, such as a pharmaceutically active ingredient, to a substrate, such as a tablet. In one aspect, the electrostatic chuck comprises a floating electrode, and is used to selectively attract particles to a substrate above the floating electrode, thereby providing for charge imaging for the deposition of particles in a selected image. Additionally, the invention provides comprising a sensing electrode, optionally for use with an electrostatic chuck, for sensing the number of particles attracted to the objects on the chuck or other substrate, thereby providing for deposition of an accurate amount of particles. Furthermore, the present invention provides objects having selected areas in which particles are applied to the object via electrostatic means.
Patients of Group A received Inferior Alveolar Nerve block anesthesia. For this block, nerve was approached from the contra-lateral side of the oral cavity over the contralateral premolars. Needle penetrated into the mandibular tissue on the average boundary of the mandibular ramus inside the pterygomandibular space and lateral to pterygomandibular fold, it advanced until bony surface was contacted. In the event that bony contact wasn't made inside 27-29 mm of needle infiltration, needle was pulled back somewhat, moved the needle further distally toward premolars. The needle was withdrew 1-2 mm after making bony contact, aspiration was performed, followed by 1.8 ml deposition of anesthetic solution.

Patients of Group B received buccal infiltration as supplementary injection technique to conventional Inferior Alveolar Nerve block, buccal infiltration was carried out. The needle was penetrated in buccal mucosa adjacent to mandibular 1st molar. After aspiration, 1.8ml of anesthetic solution was dumped in approximate time of 2 minutes using 2% lignocaine with 1:100,000 epinephrine. Following time period of 15 minutes of injection, every patient was inquired about his/her lip numbness. Patients who did not experience significant lip numbness within 15 minutes after the block was administered were excluded from the investigation and was considered ineffective. In case of positive lip numbness patient concerned teeth was isolated using rubber dam and a traditional access opening was started. Patient was told to lift hand if any pain will occur while doing procedure. The patient was requested to mark pain on visual analogue scale (VAS) after completion of treatment. Absence of pain was indicated if patient scored his/her pain ≤ 3 on VAS.
Subjects received 125 mg of either placebo IV or CG-745 IV infusion over 60 min. After 14 days wash-out period, subjects received 750 mg of either placebo (PO) or CG-750 capsule orally in the fasted state for at least 10 hours.
Subjects on this arm will be tested with the Signatera ctDNA assay while receiving treatment on a pre-specified sequence of FDA-approved drugs and drug combinations. Subjects will move through this sequence based on the results of the ctDNA assay. Subjects will move to a new drug or drug combination in the sequence when the ctDNA assay indicates a significant increase in ctDNA level. Subjects will also have imaging scans every 12 weeks while on each drug or drug combination and subjects will move to a new drug or drug combination if these scans indicate disease progression.
ARM A will receive Proteus Sensor System (PSS) first. At 12-week intervals participants will crossover to the next condition.
Subjects will undergo the BrainpalTM intervention for 24 sessions over the span of 8 weeks. Each session will take 30-minute to complete. The intervention group will undergo the BrainpalTM treatment in the first 8 weeks of the trial.
The invention relates to a veterinary anthelmintic, and particularly relates to a veterinary albendazole/ivermectin dry suspension with using convenience and significant drug effects. The dry suspension is prepared by steps of stirring 0.1-0.2 part of ivermectin and 2-4 parts of sodium carboxymethylcellulose and mixing, adding 2-4 parts of a flavoring agent after the powder is mixed uniformly, and mixing uniformly again; stirring 5-15 parts of albendazole and 10-20 parts of sodium chloride and mixing, adding 5-10 parts of sodium citrate after the powder is mixed uniformly, and mixing uniformly again; adding the former into the latter through an equivalent increment method, and stirring uniformly; adding the balance of other auxiliary material, and further uniformly stirring and mixing; and subpackaging to obtain the finished product. The other auxiliary material is soluble starch or microcrystalline cellulose. The dry suspension can be proportionally added in an automatic drinker directly for use, thus facilitating all-round dosing in a large-size livestock farm. The dry suspension avoids the toxic and side effect caused by non-uniform feed mixing, and is more convenient to use. The drug effect is remarkably enhanced, and the cost is obviously lowered in comparison with the prior art. The dry suspension has a wide application prospect.
BACKGROUND/OBJECTIVE: The effects of fathers' high-fat diet (HFD) on the reproductive health of their male offspring (HFD- F1) remain to be elucidated. Parental obesity is known to have a negative effect on offspring fertility, but there are few relevant studies on the effects of HFD-F1 on reproductive function.
METHODS: We first succeeded in establishing the HFD model, which provides a scientific basis in the analysis of HFD-F1 reproductive health. Next, we assessed biometric indices, intratesticular cellular status, seminiferous tubules and testicular transcriptomic homeostasis in HFD-F1. Finally, we examined epididymal (sperm-containing) apoptosis, as well as antioxidant properties, motility, plasma membrane oxidation, DNA damage, and sperm-egg binding in the epididymal sperm.
RESULTS: Our initial results showed that HFD-F1 mice had characteristics similar to individuals with obesity, including higher body weight and altered organ size. Despite no major changes in the types of testicular cells, we found decreased activity of important genes and noticed the presence of abnormally shaped sperm at seminiferous tubule lumen. Further analysis of HFD-F1 testes suggests that these changes might be caused by increased vulnerability to oxidative stress. Finally, we measured several sperm parameters, these results presented HFD-F1 offspring exhibited a deficiency in antioxidant properties, resulting in damaged sperm mitochondrial membrane potential, insufficient ATP content, increased DNA fragmentation, heightened plasma membrane oxidation, apoptosis-prone and decreased capacity for sperm-oocyte binding during fertilization.
CONCLUSION: HFD- F1 subfertility arises from the susceptibility of the transcriptional network to oxidative stress, resulting in reduced antioxidant properties, motility, sperm-egg binding, and elevated DNA damage. Schematic representation of the HFD-F1 oxidative stress susceptibility to subfertility. Notably, excessive accumulation of ROS surpasses the physiological threshold, thereby damaging PUFAs within the sperm plasma membrane. This oxidative assault affects crucial components such as mitochondria and DNA. Consequently, the sperm's antioxidant defense mechanisms become compromised, leading to a decline in vitality, motility, and fertility.
Mechanism of Action

Adenosine injection slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.

Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.

Hemodynamics

The intravenous bolus dose of 6 or 12 mg adenosine usually has no systemic hemodynamic effects. When larger doses are given by infusion, adenosine decreases blood pressure by decreasing peripheral resistance.

Pharmacokinetics

Intravenously administered adenosine is rapidly cleared from the circulation via cellular uptake, primarily by erythrocytes and vascular endothelial cells. This process involves a specific transmembrane nucleoside carrier system that is reversible, nonconcentrative, and bidirectionally symmetrical. Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol. Since adenosine kinase has a lower Km and Vmax than adenosine deaminase, deamination plays a significant role only when cytosolic adenosine saturates the phosphorylation pathway. Inosine formed by deamination of adenosine can leave the cell intact or can be degraded to hypoxanthine, xanthine, and ultimately uric acid. Adenosine monophosphate formed by phosphorylation of adenosine is incorporated into the high-energy phosphate pool. While extracellular adenosine is primarily cleared by cellular uptake with a half-life of less than 10 seconds in whole blood, excessive amounts may be deaminated by an ecto-form of adenosine deaminase. As adenosine requires no hepatic or renal function for its activation or inactivation, hepatic and renal failure would not be expected to alter its effectiveness or tolerability.

Clinical Trial Results

In controlled studies in the United States, bolus doses of 3, 6, 9, and 12 mg were studied. A cumulative 60% of patients with paroxysmal supraventricular tachycardia had converted to normal sinus rhythm within one minute after an intravenous bolus dose of 6 mg adenosine (some converted on 3 mg and failures were given 6 mg), and a cumulative 92% converted after a bolus dose of 12 mg. Seven to sixteen percent of patients converted after 1 to 4 placebo bolus injections. Similar responses were seen in a variety of patient subsets, including those using or not using digoxin, those with Wolff-Parkinson-White Syndrome, males, females, blacks, Caucasians, and Hispanics.

Adenosine is not effective in converting rhythms other than PSVT, such as atrial flutter, atrial fibrillation, or ventricular tachycardia, to normal sinus rhythm.
Composed of 6 commercially available computer games. It matches the experimental treatment program in overall program use intensity, time-spent attending, delivered rewards, and overall engagement.
Background: The primary objective of this study was to determine the association between preoperative electrodiagnostic study (EDS) parameters and Patient-Reported Outcomes Measurement Information System (PROMIS) instruments in patients with EDS-confirmed carpal tunnel syndrome (CTS). Methods: A retrospective study of 45 patients with EDS-confirmed CTS was conducted. Patients completed the PROMIS Upper Extremity, PROMIS Pain Interference and PROMIS Pain Intensity. Explanatory variables included EDS disease severity (mild, moderate and severe), sensory peak latency, sensory amplitude, motor latency, motor amplitude, the presence of nonrecordable sensory latency and the presence of nonrecordable sensory amplitude. Explanatory variables also included patient-related factors, such as age, sex and diabetes mellitus. Associations between variables were assessed using simple linear regression, analysis of variance (ANOVA) and Student's t-test. Results: In our cohort, the EDS severity was mild in 38%, moderate in 42% and severe in 20% of patients. The mean PROMIS Upper Extremity score was 44.4, the mean PROMIS Pain Interference score was 53.5 and the mean PROMIS Pain Intensity score was 49.9. Bivariate analysis demonstrated no association between EDS severity overall or any EDS parameter individually and PROMIS Upper Extremity, PROMIS Pain Interference and PROMIS Pain Intensity. Diabetes mellitus was associated with poorer PROMIS Upper Extremity scores. Conclusions: EDS severity is not associated with PROMIS Upper Extremity, PROMIS Pain Interference and PROMIS Pain Intensity. Carpal tunnel release is commonly indicated for pain and dysfunction, but validated measures of pain and dysfunction do not correlate with EDS severity. Level of Evidence: Level III (Diagnostic).
Cidofovir (Vistide) is a commercially available agent approved by the FDA for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). The drug is not FDA approved for the treatment of RRP at this time. However, recent case reports have been encouraging with regard to the effectiveness of the agent in the treatment of RRP. The FDA has granted this study a "safe to proceed" designation with IND 58,481.